Login to Your Account

Earnings Roundup

Thursday, March 8, 2012
• Allos Therapeutics Inc., of Westminster, Colo., reported fourth-quarter net product sales of $15.4 million for peripheral T-cell lymphoma drug Folotyn (pralatrexate), a 17 percent increase over the third quarter of 2011. For the full year, Folotyn net sales totaled $50.5 million, a 43 percent jump over 2010.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription